Your browser doesn't support javascript.
loading
Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676.
Varnäs, Katarina; Juréus, Anders; Johnström, Peter; Ahlgren, Charlotte; Schött, Pär; Schou, Magnus; Gruber, Susanne; Jerning, Eva; Malmborg, Jonas; Halldin, Christer; Afzelius, Lovisa; Farde, Lars.
Afiliação
  • Varnäs K; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Juréus A; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Johnström P; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Ahlgren C; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Schött P; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Schou M; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Gruber S; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Jerning E; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Malmborg J; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Halldin C; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Afzelius L; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
  • Farde L; Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm (K.V., P.J., M.S., C.H., L.F.); AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm (P.J., M.S., L.F.); AstraZeneca R&D, Södertälje (A.J., C.A., P.S., S.G., E.J
J Pharmacol Exp Ther ; 358(3): 464-71, 2016 09.
Article em En | MEDLINE | ID: mdl-27402278
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Psicotrópicos / Quinazolinas / Benzofuranos / Tomografia por Emissão de Pósitrons Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Psicotrópicos / Quinazolinas / Benzofuranos / Tomografia por Emissão de Pósitrons Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article